Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Total Liabilities
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has total liabilities worth $2.78 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AMRX net assets growth trend to track the company's year-over-year net asset growth rate.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Total Liabilities Trend (2015–2024)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. See Amneal Pharmaceuticals, Inc. Class A Com (AMRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hinge Health, Inc.
NYSE:HNGE
|
USA | $366.23 Million |
|
Olav Thon Eien
OL:OLT
|
Norway | Nkr32.70 Billion |
|
China Coal Xinji Energy Co Ltd
SHG:601918
|
China | CN¥30.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥3.18 Billion |
|
RUBIS
F:BYN
|
Germany | €3.71 Billion |
|
Quálitas Controladora S.A.B. de C.V.
MX:Q
|
Mexico | MX$96.22 Billion |
|
Sinomach Heavy Equipment Group Co Ltd
SHG:601399
|
China | CN¥18.98 Billion |
|
Premium Brands Holdings Corporation
TO:PBH
|
Canada | CA$5.04 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AMRX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amneal Pharmaceuticals, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below shows the annual total liabilities of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.55 Billion | +2.71% |
| 2023-12-31 | $3.45 Billion | -3.84% |
| 2022-12-31 | $3.59 Billion | +0.50% |
| 2021-12-31 | $3.57 Billion | -2.41% |
| 2020-12-31 | $3.66 Billion | +10.30% |
| 2019-12-31 | $3.32 Billion | -3.97% |
| 2018-12-31 | $3.46 Billion | +101.25% |
| 2017-12-31 | $1.72 Billion | +23.14% |
| 2016-12-31 | $1.39 Billion | +16.14% |
| 2015-12-31 | $1.20 Billion | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more